| Characteristics |
ALC-15/AMC-15 ≥ 1
(N = 120) |
ALC-15/AMC-15 < 1
(N = 136) |
P-value |
| At Diagnosis |
|
|
|
| Age, years, median (range) |
55 (22-76) |
55 (17-76) |
0.2 |
| Gender |
|
|
0.4 |
| Male |
71 (59.0%) |
87 (64.0%) |
|
| Female |
49 (41.0%) |
49 (36.0%) |
|
| Extra-nodal sites |
|
|
0.6 |
| 0 |
81 (67.5%) |
90 (66.2%) |
|
| 1 |
31 (26.0%) |
33 (24.3%) |
|
| 2 |
6 (5.0%) |
11 (8.1%) |
|
| 3 |
2 (1.5%) |
1 (0.7%) |
|
| 4 |
0 (0.0%) |
1 (0.7% |
|
| LDH (U/L), median (range) |
211 (110-2400) |
284 (111-2250) |
0.3 |
| PS |
|
|
0.1 |
| 0 |
33 (27.5%) |
23 (17.0%) |
|
| 1 |
85 (70.8%) |
107 (78.6%) |
|
| 2 |
2 (1.7%) |
6 (4.4%) |
|
| Stage |
|
|
0.9 |
| I |
13 (10.8%) |
19 (14.0%) |
|
| II |
21 (17.5%) |
22 (16.2%) |
|
| III |
26 (21.7%) |
31 (22.8%) |
|
| IV |
60 (50.0%) |
64 (47.0%) |
|
| IPI risk factors |
|
|
|
| Age, years |
|
|
0.1 |
| >60 |
38 (31.7%) |
56 (41.7%) |
|
| ≤ 60 |
82 (68.3%) |
80 (58.8%) |
|
| Extra-nodal sites |
|
|
0.5 |
| > 1 |
8 (6.7%) |
13 (9.6%) |
|
| ≤ 1 |
112 (93.3%) |
123 (90.4%) |
|
| LDH |
|
|
<0.04 |
| abnormal |
51 (42.5%) |
75 (55.2%) |
|
| normal |
69 (57.5%) |
61 (44.8%) |
|
| PS |
|
|
0.3 |
| > 1 |
2 (1.7%) |
6 (4.4%) |
|
| ≤ 1 |
118(98.3%) |
130 (95.6%) |
|
| Stage |
|
|
0.8 |
| I/II |
34 (28.0%) |
41 (30.0%) |
|
| III/IV |
86 (72%) |
95 (70.0%) |
|
| IPI score |
|
|
0.1 |
| 0 |
17 (14.0%) |
15 (11.0%) |
|
| 1 |
44 (37.0%) |
35 (26.0%) |
|
| 2 |
41 (34.0%) |
60 (44.0%) |
|
| 3 |
14 (12.0%) |
24 (18.0%) |
|
| 4 |
4 (3.0%) |
2 (1.0% |
|
| IPI |
|
|
<0.03 |
| ≥ 2 |
59 (49.0%) |
86 (63.0%) |
|
| < 2 |
61 (51.0%) |
50 (37.0%) |
|
| At relapse |
|
|
|
| IPI risk factors |
|
|
|
| Age-R |
|
|
0.2 |
| > 60 |
41 (35%) |
57 (42%) |
|
| ≤ 60 |
79 (65%) |
79 (58%) |
|
| Extra nodal sites-R |
|
|
< 0.01 |
| > 1 |
7 965) |
22 (16%) |
|
| ≤ 1 |
113 (94%) |
114 (84) |
|
| LDH-R |
|
|
<0.0001 |
| abnormal |
40 (33%) |
80 (59%) |
|
| normal |
80 (67%) |
56 (41%) |
|
| PS-R |
|
|
< 0.02 |
| > 1 |
8 (7%) |
22 (16%) |
|
| ≤ 1 |
112 (93%) |
114 (84%) |
|
| Stage-R |
|
|
<0.03 |
| I/II |
60 (50%) |
49 (36%) |
|
| III/IV |
60 (50%) |
87 (64 %) |
|
| IPI-R |
|
|
<0.0004 |
| >2 |
16 (13%) |
44 (32%) |
|
| ≤ 2 |
104 (87 %) |
92 (68%) |
|
| Pre-transplant Rituximab |
|
|
0.3 |
| No |
61 (515) |
76 (56%) |
|
| Yes |
59 (49%) |
60 (445) |
|
| Number of prior treatments before transplant |
|
|
0.1 |
| 2 |
108 (90%) |
112 (81%) |
|
| 3 |
10 (8%) |
23 (17%) |
|
| 4 |
2 (2%) |
1 91%) |
|
| At transplant |
|
|
|
| Age, years, median (range) |
55.5 (22-77) |
59 (17-76) |
0.2 |
| Outcome prior to transplant |
|
|
<0.02 |
| CR |
39 (33.0%) |
27 (20.0%) |
|
| PR |
81 (67.0%) |
109 (80.0%) |
|
| Conditioning regimens |
|
|
0.7 |
| CTX/TBI |
2 (2.0%) |
4 (3.0%) |
|
| BEAC |
21 (18.0%) |
26 (19.0%) |
|
| BEAM |
97 (80.0%) |
106 (78.0%) |
|
| Infused CD34, median (range) |
3.56 (2.0-14.85) |
3.14 (2.0-11.06) |
0.4 |
Abbreviations: Age-R= age at relapse; Extra nodal sites-R = extranodal sites
at relapse; LDH = lactate dehydrogenase; LDH-R = lactate dehydrogenase at
relapse; PS = performance status; PS-R; performance status at relapse; Stage-R
= stage at relapse; IPI = International Prognostic Index; IPI-R = International
Prognostic Index at relapse; CTX= cyclophosphamide; TBI = Total body
irradiation: BEAC = BCNU, etoposide, Ara-C, and cyclophosphamide; BEAM =
BCNU, etoposide, Ara-C, and melphalan; CR = complete remission; PR = partial
response. |
